We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Stock Moves -0.05%: What You Should Know
Read MoreHide Full Article
The latest trading session saw Eli Lilly (LLY - Free Report) ending at $778.62, denoting a -0.05% adjustment from its last day's close. The stock's change was more than the S&P 500's daily loss of 0.39%. Meanwhile, the Dow lost 0.61%, and the Nasdaq, a tech-heavy index, lost 0.32%.
Coming into today, shares of the drugmaker had gained 7.12% in the past month. In that same time, the Medical sector lost 0.78%, while the S&P 500 gained 3.6%.
The investment community will be closely monitoring the performance of Eli Lilly in its forthcoming earnings report. The company's upcoming EPS is projected at $5.49, signifying a 120.48% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $14.08 billion, up 50.57% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $13.17 per share and a revenue of $45.59 billion, representing changes of +108.39% and +33.62%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Eli Lilly. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.23% downward. Right now, Eli Lilly possesses a Zacks Rank of #3 (Hold).
Looking at its valuation, Eli Lilly is holding a Forward P/E ratio of 59.16. This denotes a premium relative to the industry's average Forward P/E of 13.9.
Investors should also note that LLY has a PEG ratio of 2.96 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.46 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 157, putting it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Eli Lilly (LLY) Stock Moves -0.05%: What You Should Know
The latest trading session saw Eli Lilly (LLY - Free Report) ending at $778.62, denoting a -0.05% adjustment from its last day's close. The stock's change was more than the S&P 500's daily loss of 0.39%. Meanwhile, the Dow lost 0.61%, and the Nasdaq, a tech-heavy index, lost 0.32%.
Coming into today, shares of the drugmaker had gained 7.12% in the past month. In that same time, the Medical sector lost 0.78%, while the S&P 500 gained 3.6%.
The investment community will be closely monitoring the performance of Eli Lilly in its forthcoming earnings report. The company's upcoming EPS is projected at $5.49, signifying a 120.48% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $14.08 billion, up 50.57% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $13.17 per share and a revenue of $45.59 billion, representing changes of +108.39% and +33.62%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Eli Lilly. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.23% downward. Right now, Eli Lilly possesses a Zacks Rank of #3 (Hold).
Looking at its valuation, Eli Lilly is holding a Forward P/E ratio of 59.16. This denotes a premium relative to the industry's average Forward P/E of 13.9.
Investors should also note that LLY has a PEG ratio of 2.96 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.46 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 157, putting it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.